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The human ABCB1 (MDR1)-encoded multidrug transporter P-glycoprotein (P-gp) plays a major role in disposition and
efficacy of a broad range of drugs including anticancer agents. ABCB1 polymorphisms could therefore determine
interindividual variability in resistance to these drugs. To test this hypothesis we developed a Saccharomyces-based
assay for evaluating the functional significance of ABCB1 polymorphisms. The P-gp reference and nine variants
carrying amino-acid–altering single nucleotide polymorphisms (SNPs) were tested on medium containing
daunorubicin, doxorubicin, valinomycin, or actinomycin D, revealing SNPs that increased (M89T, L662R, R669C, and
S1141T) or decreased (W1108R) drug resistance. The R669C allele’s highly elevated resistance was compromised when
in combination with W1108R. Protein level or subcellular location of each variant did not account for the observed
phenotypes. The relative resistance profile of the variants differed with drug substrates. This study established a
robust new methodology for identification of function-altering polymorphisms in human multidrug transporter genes,
identified polymorphisms affecting P-gp function, and provided a step toward genotype-determined dosing of
chemotherapeutics.
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Introduction
Patients vary widely in their drug responses including
unpredicted adverse drug reactions that cause a signiﬁcant
loss of lives and a huge toll on health-care costs [1]. Rational
selection and dosage optimization of anticancer agents are
particularly important due to their narrow therapeutic index
and inherent cytotoxicity. Membrane transporters affect drug
disposition and response by determining whether or not the
level of drug is maintained within the therapeutic index. Of
the known human transporters, P-glycoprotein (P-gp) is of
particular clinical relevance in that this multidrug efﬂux
pump has a broad range of substrates, including structurally
and functionally divergent drugs in common clinical use [2–
4]. P-Gp belongs to the ATP-binding cassette (ABC) super-
family [5] and is encoded by the human ABCB1 gene (also
known as multidrug resistance 1 gene [MDR1]). Multidrug
resistance caused by ABCB1 ampliﬁcation is a major obstacle
in cancer chemotherapy. In fact, the ABCB1 gene was
originally identiﬁed because of its ampliﬁcation in tumor
cells that had acquired cross-resistance to multiple cytotoxic
anticancer agents [2,6–9]. P-Gp is expressed in many tissues,
suggestive of a broad physiological role [10,11] and functions
by pumping cytotoxic drugs and xenotoxins out of cells into
the intestinal lumen, bile, and urine, and thus limiting
distribution of such compounds to other organs.
Genetic heterogeneity of the ABCB1 gene may be a potent
determinant of interindividual variability in resistance to
multiple drugs including anticancer agents. Furthermore, P-
gp can act alone or in combination with other genetic
variants, particularly polymorphisms in CYP3A4, a cyto-
chrome P450 monooxygenase that metabolizes a wide range
of drugs [12,13]. Naturally occurring null mutations in P-gp
have been reported in mice and dogs but not in humans
[14,15]. Animals carrying a null ABCB1 variant are viable
unless challenged by drugs that are substrates for P-gp.
Likewise, there may be unidentiﬁed human ABCB1 variants
that cause a total loss of function. Numerous ABCB1 single
nucleotide polymorphisms (SNPs) have been identiﬁed.
However, the correlation of SNPs with ABCB1 expression
and P-gp function in clinical pharmacokinetics has been
inconclusive. A synonymous 3435C.T SNP has been heavily
studied, but its function remains under debate [16]. More-
over, to date there have been no naturally occurring
nonsynonymous substitutions with a validated functional
consequence [17]. Robust functional assays of P-gp variants at
the cellular and molecular levels are needed to address their
impact on clinical pharmacokinetics.
Since human populations are outbred, and each individual
is heterozygous for several million polymorphisms, the
impact of ABCB1 variants is difﬁcult to separate from the
potential contributions of other variations in an individual.
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foreign eukaryotic transport proteins [18]. Expressing human
proteins and their variants in yeast allows the function of
individual variants to be assessed directly. The human P-gp
can be functionally expressed in the yeast Saccharomyces
cerevisiae, where it exports at least some of the same
compounds that it exports in human cells [19]. A typical
assay for human P-gp function in yeast involves testing its
ability to restore growth to cells in the presence of
compounds that would otherwise block their growth. This
functional complementation in yeast allows the impact of
ABCB1 variants found in human populations to be assessed.
This study tested the functional consequences of ABCB1
genetic variants found in ethnically diverse populations
(Figure S1) [20]. From this dataset (http://pharmacogenetics.
ucsf.edu or http://www.pharmgkb.org), we prioritized non-
synonymous SNPs by their predicted impact on P-gp
function, selected ten haplotypes carrying high-priority
SNP(s), and determined the level of resistance caused by
these ABCB1 variants to clinically important drugs. For those
Figure 1. Functional Complementation of Human cDNAs for P-Gp Variants in a Drug-Sensitive Yeast Strain
(A) Differences in drug sensitivity of yeast strains. Yeast strains tested included mutants in which combinations of three major endogenous multidrug
transporter genes, PDR5, SNQ2, and YOR1, were deleted. Cultures from each strain were adjusted to the same cell concentration and serially diluted 5-
fold. The genotypes of the strains tested are shown in Table S1. The pdr5 snq2 yor1 triple mutant was consistently the most sensitive strain to
daunorubicin and doxorubicin.
(B) Restoration of drug resistance in the hyper-sensitized yeast strain by P-gp variants. Cultures from each strain were adjusted to the same cell
concentration and serially diluted 5-fold. Variants restored drug resistance of the hyper-sensitized yeast strain to varying degrees. The strains tested are
pdr5 snq2 yor1 with plasmids carrying the indicated variants (Table S1). A frame-shifted P-gp was used as a negative control.
doi:10.1371/journal.pgen.0030039.g001
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Author Summary
Patients often show varied drug responses ranging from lack of
therapeutic efficacy to life-threatening adverse drug reactions. Drug
therapy would be greatly improved if it were possible to predict
individual drug sensitivity and tailor drugs to patients’ genetic
makeup. Like all other organisms, humans have a set of transporters
and enzymes to detoxify and eliminate foreign molecules including
drugs. Understanding the function of genetic variants in these
proteins is a key goal toward personalized medicine. To that end, we
examined the functional consequences of naturally occurring
genetic variants in P-glycoprotein, the most versatile human
multidrug transporter. A novel method was developed and
employed that can identify function-altering variants in human
transporters. This methodology was robust and powerful in that the
functional effect of genetic variants can be directly assessed in yeast
where all confounding variables in humans are excluded. Surpris-
ingly, the majority of single amino acid substitutions were found to
cause alterations in resistance to three tested anticancer agents. This
study extends the impact of yeast-based medical research to a new
niche, pharmacogenomics.variants that altered function, subsequent experiments tested
the mechanism of these effects.
Results
The Human ABCB1 Gene Functioned in Hyper-Sensitized
Yeast Cells
As the ﬁrst step toward functional analysis of the non-
synonymous variants of human P-gp, we tested the sensitivity
of yeast strains harboring mutations in major endogenous
multidrug transporter genes, PDR5, SNQ2,a n dYOR1.
Combinatorial deletions of these three genes confer sensi-
tivity to a variety of toxic compounds including two
anticancer agents, daunorubicin and doxorubicin, which are
substrates for human P-gp [21]. The double mutant pdr5 yor1
(JRY8008) displayed increased sensitivity relative to wild-type
cells toward doxorubicin, whereas another double mutant
pdr5 snq2 (JRY8004) displayed increased sensitivity toward
daunorubicin and doxorubicin. The strain that exhibited the
greatest drug sensitivity was the pdr5 snq2 yor1 triple deletion
mutant (JRY8012) (Figure 1A) (see Table S1 for the strain list).
This result was reminiscent of bacterial multidrug efﬂux
pumps that produce greater drug resistance in combination
than alone [22].
To address the function of human P-gp in yeast, we used a
plasmid (pJR2702) that contains a cDNA for the human
ABCB1 gene expressed from the promoter for the S. cerevisiae
STE6 gene on a multicopy vector [19]. The yeast STE6 gene
encodes an ABC transporter that mediates the export of the
a-factor pheromone in MATa cells. The cloned cDNA carried
the G185V SNP of ABCB1, and therefore site-directed
mutagenesis was used to restore it to the most common
allele, referred to as the ABCB1 reference allele in the
Pharmacogenetics of Membrane Transporters dataset
(pJR2703) (http://pharmacogenetics.ucsf.edu or http://www.
pharmgkb.org). Cells expressing the ABCB1 reference cDNA
from the multicopy plasmid in the pdr5 snq2 yor1 strain
showed highly increased resistance towards daunorubicin and
doxorubicin relative to that of the pdr5 snq2 yor1 strain
(Figure 1B). Thus the P-gp reference was functionally
expressed in these yeast cells.
Prediction of Functional Impact of SNPs by Evolutionary
Conservation and Chemical Dissimilarity
The Pharmacogenetics of Membrane Transporters study
identiﬁed fourteen nonsynonymous SNPs in 247 healthy
individuals from an ethnically diverse population (Figure S1)
[20]. These SNPs comprised 25 haplotypes including 15
haplotypes in which the phase relationship of the SNPs was
inferred but not directly resolved. SNPs were prioritized for
functional analysis by two criteria: the degree of evolutionary
conservation [23] and the biochemical severity of the
alteration. The extent of evolutionary sequence conservation
and thus inferred constraint at a particular residue was
observed across ten mammalian species. The severity of
missense changes was estimated by the Grantham scale [24],
which formulates the difference in codon substitutions based
on chemical dissimilarity of the encoded amino acids.
Grantham values range between 5 and 215, with higher
values indicating more radical chemical changes.
Out of the 14 nonsynonymous SNPs in the dataset [20], we
chose seven SNPs for functional characterization (Table 1).
We ﬁrst focused on the ﬁve SNPs with highest Grantham
values (.80): M89T, L662R, R669C, A893S, and W1108R. The
M89T polymorphic site was not evolutionarily conserved, but
the other four sites were highly conserved. In addition, the
P1051A SNP was chosen because of its conservation despite a
low Grantham value, and the S1141T SNP was included due
to its relatively high allele frequency (11% in African
Americans) and evolutionary conservation. Although A893S,
S1141T, and R669C SNPs are common variants (minor allele
frequency  1% in at least one major ethnic group), the
remaining four chosen variants are observed only once
among 494 alleles from different populations. These rare
variants (minor allele frequency ,1%) were included because
rare adverse drug reactions may be due to highly penetrant
but rare variants. The alignment and allele count of ABCB1
haplotypes based on the 14 nonsynonymous SNPs identiﬁed
in the previous resequencing project are presented in Table
S2. From the standpoint of functional impact, the R669C SNP
was particularly interesting. First, this Arg-to-Cys substitution
had the highest Grantham value (180) among the fourteen
SNPs. Second, this SNP was observed twice in the African
American population exhibiting a 1% allele frequency,
whereas the four chosen rare variants occurred only once.
Third, the R669C SNP may be in phase with the W1108R
variant. One of the two R669C SNPs was detected in an
individual whose ABCB1 gene also contained the W1108R
variant, potentially resulting in haplotype R669C-W1108R.
This observation prompted us to test whether a R669C-
W1108R allele had a unique phenotype relative to alleles
carrying each individual SNP.
P-Gp Variants Exhibited Altered Resistance to Two
Anticancer Agents
We constructed plasmids expressing P-gp variants by site-
directed mutagenesis on the reference plasmid to evaluate
the effect of selected SNPs and their combinations on P-gp
function. These plasmids (pJR2703–pJR2712), along with two
control vectors (YEp352 and pJR2713), were transformed into
Table 1. Features of the ABCB1 Variants Analyzed in This Study
SNP
a Evolutionary
Conservation
b
Chemical
Dissimilarity
(Grantham Value
c)
Allele Count
(out of 494
Alleles)
M89T 0 81 1
L662R 3 102 1
R669C 2 180 2
A893S 2 99 151
P1051A 3 27 1
W1108R 3 101 1
S1141T 3 58 23
aPositions are relative to the transcription start site and based on the cDNA sequence
from GenBank accession number M14758.1 with the change V185G, which is the most
common haplotype in African Americans in the Pharmacogenetics of Membrane
Transporters dataset.
bNumbers represent 100% identical, well-conserved, poorly-conserved, and unconserved
as 3, 2, 1, and 0, respectively, based on sequence alignments with nine mammalian
orthologs by Clustal.
cGrantham values range from 5 to 215, in which higher values indicate more radical
chemical changes.
doi:10.1371/journal.pgen.0030039.t001
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Function-Altering SNPs in ABCB1 GeneFigure 2. Alterations in Resistance of P-Gp Variants to Daunorubicin and Doxorubicin
(A) Drug resistance of P-gp variants measured with a plating assay on solid medium. Cultures from each strain were adjusted to the same cell
concentration and spread on plates carrying daunorubicin (27.5 lM) or doxorubicin (12.5 lM). Yeast expressing P-gp variants survived on these high-
concentration drug plates to varying degrees. Daunorubicin plates for each of the P-gp variants are presented. The corresponding plates for
doxorubicin showed similar variability.
(B) Drug resistance of P-gp variants represented by colony numbers surviving on the high-concentration drug plates. Each value represents the average
6 standard deviation of three measurements. The values with significant differences (p , 0.05) are marked with *.
(C) Drug resistance of P-gp variants in liquid medium. Each EC50 value represents the average 6 standard deviation of three or four measurements. The
values with significant differences (p , 0.05) are marked with *.
doi:10.1371/journal.pgen.0030039.g002
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Function-Altering SNPs in ABCB1 Genethe pdr5 snq2 yor1 strain (JRY8012). These yeast strains
carrying plasmids with ABCB1 variants (JRY8025–JRY8036)
were examined for their level of resistance to daunorubicin
and doxorubicin on solid medium. Different P-gp variants
displayed higher levels of resistance (A893S-M89T, L662R,
and R669C) or lower levels of resistance (A893S, S1141T,
A893S-R669C, A893S-P1051A, W1108R, and W1108R-R669C)
relative to the P-gp reference (Figure 2A and 2B). The alleles
varied widely in their ability to survive on high concen-
trations of daunorubicin and doxorubicin. The replacement
of Arg669 by Cys led to one of the most drastic gain-of-
function effects on the ability of P-gp to confer drug
resistance. This allele’s elevated resistance was compromised
when in combination with W1108R. Cells expressing trun-
cated P-gp (see Materials and Methods) were indistinguish-
able from cells transformed with an empty vector with
respect to drug resistance.
To quantify the extent of drug cytotoxicity in liquid
medium, median effective concentration (EC50) values were
measured for daunorubicin and doxorubicin for each P-gp
variant in liquid culture (Figure 2C). For the majority of the
variants, these results were consistent with those observed in
the plate assay. However, the plate assay was more sensitive,
allowing variants that were indistinguishable from each other
in the liquid assay to be ranked. There was a discrepancy
between the two drug resistance phenotypes with the A893S
and A893S-R669 variants: the variants showed a slightly
higher level of drug resistance relative to that of the reference
in the liquid assay, but a lower survival in the plate assay. This
difference presumably reﬂects the nature of the two assays:
the plate assay measures the level of cell survival on a
relatively high ﬁxed concentration of the drug, whereas the
liquid assay determines growth rate over multiple drug
concentrations. In the plate assay, all variants for daunor-
ubicin and six variants for doxorubicin exhibited statistically
signiﬁcant differences (p , 0.05) (Figure 2B; Table S3). In the
liquid assay, three variants for daunorubicin (A893S-R669C,
A893S-M89T, and R669C) and ﬁve variants for doxorubicin
(A893S, S1141T, A893S-M89T, L662R, and R669C) exhibited
statistically signiﬁcant increases in EC50 values (p , 0.05)
(Figure 2C; Table S4).
P-Gp and Its Variants Had Similar Protein Level and
Subcellular Localization
To determine whether the observed differences in drug
resistance were due to differences in protein level, we
measured the protein level of each P-gp variant by
immunoblotting. The mouse anti-P-gp antibody detected P-
gps with an apparent molecular mass of 125 kDa, the
expected size of unglycosylated P-gp, in membranes from
yeast cells transformed with plasmids carrying reference and
variant ABCB1 genes, but not in membranes from control
cells transformed with an empty vector. The amount of P-gp
reference and variants differed by no more than 1.5-fold
Figure 3. Protein Level and Subcellular Localization of P-Gp Variants
(A) Immunoblot analysis for P-gp variants expressed in the plasma membrane fraction of yeast cells. Two-color immunoblot detection was used to
quantify the level of P-gp variants compared with the level of yeast Gas1, a membrane protein-loading control. The positions of molecular standards (in
kilodaltons) are indicated at the left. The arrows at the right indicate the position of the P-gp and Gas1 proteins expressed in yeast cells. All P-gp variants
were expressed within a 1.5-fold range from the reference P-gp. The average 6 standard deviation of three measurements of relative protein levels is
103 6 19 for A893S, 83 6 17 for S1141T, 94 6 16 for A893S-R669C, 115 6 20 for A893S-M89T, 93 6 19 for L662R, 70 6 22 for A893S-P1051A, 134 6 25
for R669C, 102 6 18 for W1108R, 148 6 24 for R669C-W1108R, and 53 6 13 for frame-shifted, relative to the average of reference P-gp set to 100. The
cells expressing the frame-shifted P-gp produced the least amount. The truncated length of the frame-shifted protein was not recognized in this gel.
(B) The relationship between daunorubicin resistance and P-Gp protein levels. The x-axis shows the relative protein level for each variant protein with
the level for the reference set at 100. The y-axis shows daunorubicin resistance represented as colony numbers surviving on the high-concentration
daunorubicin plates.
(C) Subcellular localization of GFP-fused P-Gp variants. P-Gp variants were localized to the plasma membrane and the vacuolar membrane in yeast cells.
The images were taken when the cells reached midexponential phase (OD600¼0.7). The cells expressing each P-gp variant fluoresced to similar extents,
regardless of the drug resistance phenotypes.
doi:10.1371/journal.pgen.0030039.g003
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Function-Altering SNPs in ABCB1 Gene(Figure 3A). The correlation coefﬁcient of the extent of
daunorubicin cytotoxicity of each variant relative to the
protein level of each variant was 0.227 (Figure 3B). Thus the
P-gp variants were present at comparable levels and altered
drug cytotoxicity in the variants was not due to the differ-
ences in protein levels for P-gp.
In principle, the differing drug resistance of the variants
might reﬂect differences in their subcellular localization if
the SNPs affected the P-gp trafﬁcking. To test this possibility,
strains carrying green ﬂuorescent protein (GFP) fused in
frame to the C terminus of each P-gp variant were evaluated
for their subcellular localization patterns. Fluorescence
microscopy indicated that the fusion proteins were localized
to both the plasma membrane and the vacuolar membrane in
living cells (Figure 3C). The localization patterns were
growth-phase–dependent: GFP ﬂuorescence was observed
Figure 4. Comparison of Resistance of the P-Gp Variants to Different Drug Substrates
(A) Alterations in resistance of P-gp variants to valinomycin and actinomycin D. The degree of resistance of the variants to valinomycin and actinomycin
D are presented as EC30 and EC50 values, respectively. Each EC30 or EC50 value represents the average 6 standard deviation of three measurements. The
values with significant differences (p , 0.05) are marked with *.
(B) Correlation of the drug resistance profiles for different drug substrates. The correlation coefficients for each pair of EC50 (or EC30) values are
presented.
doi:10.1371/journal.pgen.0030039.g004
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Function-Altering SNPs in ABCB1 Genemostly in the plasma membrane in mid-log phase cells and
became more concentrated in vacuoles when the cells were
grown into the stationary phase. The cells carrying each of
the GFP-fused P-gp variants ﬂuoresced to similar extents
from the same subcellular location under each growth phase.
Thus differences in subcellular localization were unlikely to
underlie the differences in drug resistance associated with the
variants.
The Relative Resistance Profile of the Variants Differed
with the Drug Substrates
The relative resistance of each P-gp variant to the
structurally similar drugs, daunorubicin and doxorubicin,
were quite similar (Figure 2). Because P-gp can confer cellular
resistance to a variety of cytotoxic drugs, we tested whether P-
gp variants might exhibit different resistance proﬁles when
tested with additional P-gp substrates, valinomycin and
actinomycin D, which are structurally dissimilar from
daunorubicin and doxorubicin. Due to the limited solubility
of valinomycin in synthetic (CSM)–Ura culture medium,
determining the EC50 values was not possible. However,
determining the EC30 proved sufﬁcient to distinguish among
the P-gp variants for valinomycin resistance (Figure 4A).
Although some alleles showed similar trends of resistance for
valinomycin and daunorubicin/doxorubicin, others (e.g.,
S1141T, W1108R, and W1108R-R669C) were qualitatively
different in their resistances.
Yeast MATa ste6 strains, which lack the a factor pheromone
transporter, are reported to be more sensitive to actinomycin
D than wild-type strains [25]. This prompted us to investigate
the interesting possibility that MATa cells are intrinsically
more resistant to actinomycin D than MATa cells. Indeed
MATa cells were dramatically more sensitive to actinomycin
D (EC50 15 lg/ml) than MATa cells (EC50 48 lg/ml). To see if
the cytotoxicity proﬁle pattern of P-gp variants is changed
with actinomycin D, all variants were tested in a MATa ste6
strain (JRY8572) for their levels of resistance to actinomycin
D (JRY8573–JRY8584) (Figure 4A).
We tested the statistical signiﬁcance of all comparisons
between the reference and each variant for each drug (Table
S4). Five variants (S1141T, A893S-R669C, A893S-M89T,
L662R, and R669C) exhibited a statistically signiﬁcant
increase in EC50 or EC30 values for two or more drugs. The
A893S and A893S-P1051A variants caused an increase in
resistance only for doxorubicin and valinomycin, respec-
tively. The compromising effect of W1108R on R669C was
obvious in resistance for all four drugs (Figures 2 and 4A). To
see if the relative resistance proﬁle of the P-gp variants to one
substrate was predictive of the relative resistance proﬁle to
other substrates, we determined the correlation coefﬁcient
for all combinatorial pairs of the four relative resistance
proﬁles (Figure 4B). The resistance proﬁles of three anti-
cancer agents (daunorubicin, doxorubicin, and actinomycin
D) were highly correlated to each other, whereas the
resistance proﬁle of valinomycin exhibited a relatively low
degree of correlation with those of the other three drugs.
Discussion
To understand the correlation between ABCB1 polymor-
phisms and altered cellular pharmacokinetics, we have
developed functional assays of P-gp variants in yeast cells.
The function of nonsynonymous SNPs was quantitatively
measured in isolation from all other variations in the human
genome in a yeast-based in vivo assay. The most sensitive
measure of drug transport was a colony-counting assay,
which provided both qualitative and quantitative measures of
drug resistance in yeast expressing reference and variant P-
gp. We observed multiple differences caused by the P-gp
variants in the level of resistance to the anticancer agents,
daunorubicin, doxorubicin, and actinomycin D, and the
potassium ionophore valinomycin. The functional conse-
quences of ﬁve ABCB1 polymorphisms were previously
unknown: the M89T, L662R, R669C, and S1141T variants
were associated with increased resistance to two or more
drugs; and the W1108R variant strongly mitigated the impact
of R669C on gain of P-gp function (Figures 2 and 4A). Due to
its high allele frequency (11% in African Americans), the
S1141T SNP in particular deserves further attention to deﬁne
its clinical signiﬁcance. As measured by plating efﬁciency in
an acute exposure test, the difference between the reference
and most sensitive (W1108R) alleles was approximately 30-
fold. In a chronic exposure involving growth in the presence
of the drug, like most quantitative comparisons of the activity
of single amino acid substituted P-gp mutants in the
published data, the differences among the P-gp variant
alleles in EC50 or EC30 values were modest in most cases.
The functional variations can be magniﬁed in clinical
practice, especially for anticancer agents due to ABCB1
ampliﬁcation in cancer patients. In previous studies, the
A893 variant, which is the most common SNP, caused either
no signiﬁcant functional impact [20,26,27] or increased P-gp
function for digoxin efﬂux [28]. The data shown here were
able to detect an effect of this allele and uncovered
unexpected complexity in the response. In the acute assay,
A893S cells were signiﬁcantly more sensitive to both
daunorubicin and doxorubicin than cells with the reference
allele (Figure 2A and 2B). In contrast, in the chronic assay the
A893S allele was indistinguishable from the reference allele
with respect to daunorubicin and slightly more resistant to
doxorubicin (Figure 2C).
Like variants of facilitated drug inﬂux pumps in the solute-
carrier superfamily, P-gp variants that increased function
were common. Most random changes in protein sequence are
expected to be deleterious or neutral. The signiﬁcant
enhancement of function common to the alleles tested here
may reﬂect a recent adaptation of human populations to
local conditions like toxin exposure, leading to selective
pressures on medically relevant phenotypes. Interestingly, in
Europeans CYP genes encoding drug-metabolizing enzymes
show strong signals of very recent positive selection [29].
Despite its distinct chemical structure, the resistance
proﬁle of actinomycin D showed a high level of correlation
with those of the other anticancer agents, daunorubicin and
doxorubicin (Figure 4B). Valinomycin, which lowers the
mitochondrial membrane potential, inducing apoptosis in
some cell lines [30], exhibited a low correlation in resistance
relative to other drugs, presumably reﬂecting differences
among P-gp variants in recognition or transport of the drugs.
The resistance proﬁles of the S1141T, W1108R, and W1108R-
R669C variants showed the largest variation across substrates.
Based on this ﬁnding, we speculate that the region containing
W1108 and S1141 contributes to the substrate discrimination
activity of P-gp. To date, all mutations that alter substrate
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Function-Altering SNPs in ABCB1 Genespeciﬁcity of P-gp have been located in the transmembrane
domains [16]. In contrast, all seven SNPs for which functional
consequences were determined in this study are located
either in the extracellular region (M89T) or in the cytoplas-
mic region (the remaining six variants).
We used two widely accepted criteria for predicting the
functional effect of uncharacterized SNPs to prioritize for
functional characterization (Table 1). Our data on functional
consequences revealed that these predictions were sound:
four functional SNPs (L662R, R669C, W1108R, and S1141T)
scored highly on both criteria, while the two SNPs (A893S and
P1051A) that showed no signiﬁcant functional impact had
lower scores on evolutionary conservation and chemical
dissimilarity, respectively. One exception was the M89T
variant that altered function despite being poorly conserved
among mammals.
Most previous functional studies focused on the impact of
individual SNPs rather than that of haplotypes. However, in
at least some cases, drug response correlates with the patients’
haplotypes rather than individual SNPs [31,32]. We tested
SNP interactions to see if a compound allele consisting of two
SNPs has a unique phenotype different from those of single-
SNP alleles. Indeed, it is striking that the strong impact of
R669C on P-gp function diminished almost completely when
combined with W1108R (Figures 2 and 4A). In contrast, the
W1108R variant either alone or with A893S contributed no
signiﬁcant alterations in EC50 or EC30 values. This result
highlighted the importance of testing the impact of all
substitutions in a gene together and suggests that compensa-
tory SNPs may exist in nature.
SNPs in the ABCB1 gene have been implicated in altering
drug response or susceptibility to diseases such as Parkinson’s
disease [33], inﬂammatory bowel disease [34], and renal
epithelial tumors [35]. However, in many such cases, the
reported effects of ABCB1 polymorphisms are conﬂicting or
inconsistent [26,36–38]. This inconsistency may have several
causes. First, P-gp expression levels may be modiﬁed by
nongenetic factors, such as diet and comedications, especially
when surgical specimens are studied. Second, previous studies
with mammalian cell lines rely on transient expression assays,
which swamp the subtle effects of SNPs by variable levels of
expression. Third, only a few coding SNPs have been
functionally tested, such as A893S and N21D, which our
analysis predicted would have a weak functional impact [26].
The use of yeast to evaluate the function of nonsynonymous
coding SNPs bypasses these issues and allows the function of
single coding SNPs and haplotypes to be assessed directly,
independent of all other variations in their original human
genome. This ‘‘in yeast pharmacogenetics’’ can function as a
robust screening and phenotyping tool to characterize
additional SNPs in ABCB1 and presumably other human
multidrug transporter genes.
During the course of these studies, we observed that MATa
cells were highly sensitive to actinomycin D, whereas MATa
cells were resistant. This was apparently due to expulsion of
the drug by the a cell-speciﬁc Ste6 transporter. Perhaps
chemical exposures in ecological niches or the consequences
of treatment with therapeutics might lead to the extreme
mating-type biases observed with some fungal pathogens. For
example, the mating-type–speciﬁc niches occupied by Crypto-
coccus neoformans may reﬂect the ability to transport toxins out
of the cell in certain environments [39].
Materials and Methods
Yeast strains and growth conditions. S. cerevisiae strains used in this
study are listed in Table S1. Standard rich medium (YPD), CSM, and
synthetic medium lacking nutritional supplement(s) (CSM–Ura,
CSM–His, and CSM–Ura–Trp) were prepared as described [40]. Yeast
cells were grown routinely at 30 8C.
Plasmids. A P-gp-expressing plasmid, pJR2702 (alias pYKM77; a
multicopy-number vector), was kindly provided by Jeremy Thorner
(University of California, Berkeley, California, United States) and
used for constructing expression plasmids for ABCB1 bearing
different SNPs. A cDNA for the human ABCB1 coding sequence
(GenBank accession number M14758.1) was cloned into a multicopy
URA3-marked plasmid with the 2 lm origin of replication (YEp352)
and expressed from the yeast STE6 promoter (pJR2702). Substitutions
at the SNP position were carried out in pJR2702 by site-directed
mutagenesis with primers designed to generate individual haplotypes
(Table S5), using the QuikChange site-directed mutagenesis kit from
Stratagene (http://www.stratagene.com). We introduced ﬁve single
SNP alleles and four compound alleles consisting of a two-SNP
haplotype into the reference plasmid (pJR2703), creating plasmids
pJR2704 to pJR2712 (Table S1). As a negative control, a 1 frameshift
mutation at codon 1,200 of the ABCB1 sequence (1,280 amino acids)
was constructed; this cDNA encodes a truncated product of 1,228
amino acids expected to be nonfunctional when expressed (pJR2713).
Presence of the desired substitution in the plasmids was veriﬁed by
DNA sequencing. These eleven constructs, along with another control
lacking the entire ABCB1 sequence (pJR1016), were transformed into
a MATa yeast strain lacking three different ABC transporter genes
(Dpdr5 Dsnq2 Dyor1, JRY8012), resulting in strains JRY8025 to JRY8036
(Table S1).
Drug compounds. Daunorubicin and doxorubicin were kindly
provided by Robert Schultz in the Developmental Therapeutics
Program of the National Cancer Institute, National Institutes of
Health (NIH) (Rockville, Maryland, USA). Valinomycin and actino-
mycin D were from Sigma (http://www.sigmaaldrich.com). For drug
cytotoxicity assays, stock solutions of the drug were prepared at 10
mM in 5% DMSO for daunorubicin and doxorubicin, in 98% ethanol
for valinomycin, and in 100% DMSO for actinomycin D.
Drug cytotoxicity assays. In the spotting assay, cultures from each
strain were grown to midexponential phase, titrated to the same
concentration (;10
7 cells per 1 ml), and serially diluted 5-fold.
Aliquots (4 ll) from the dilution series were spotted onto a CSM–Ura
plate containing the indicated concentration of the drug. Control
plates lacking the drug contained the solvent control at the same
concentrations as CSM–Ura plates containing the drug. In the plate
assay, cultures from each strain were grown to midexponential phase
and titrated to the same concentration (;10
5 cells per 1 ml). Aliquots
(100 ll) were spread onto a CSM–Ura plate containing the indicated
concentration of the drug. The same aliquots were further diluted 20-
fold (;5,000 cells per 1 ml) and spread onto control plates lacking the
drug. After incubation for three days, colony numbers per plate were
counted.
Drug resistance was further assayed quantitatively in 96-well
microtiter plates (Corning, http://www.corning.com), containing
equal volumes (200 ll) of CSM–Ura liquid medium with different
concentrations of the drug. Yeast transformants grown to stationary
phase in CSM–Ura were diluted to an OD600 of 0.1. Equal volumes
(200 ll) of these diluted cultures containing increasing concentra-
tions of the drug were added to wells and incubated at 30 8C for 24 h
in a Tecan microtiter plate reader. Cell growth was monitored in the
absence of the drug in the presence of the same solvent as a negative
control. For the experiments with liquid medium, the EC50 (median
effective concentration) value was deﬁned as the drug concentration
that reduced growth of the treated cells to 50% of growth of the
control cultures as judged by OD600 when the increase in OD600 of the
control cultures was 0.7 (midexponential phase). To rule out the
possibility that variations in copy number affect the observed
differences in drug resistance for the vectors bearing each P-gp
variant, all measurements were examined in a series of independent
transformants for each of the P-gp variants.
Preparation of membrane extracts. Membrane fractions of yeast
cells with the plasmids bearing ABCB1 variants (JRY8025–JRY8036)
were prepared as described [41].
Detection and quantiﬁcation of P-gp variant proteins by immuno-
blotting. The mouse monoclonal anti-P-gp antibody C219, kindly
provided by Michael Gottesman (National Cancer Institute, NIH,
Bethesda, Maryland, United States), was used in immunoblots to
quantify the level of P-gp variants in yeast. A rabbit antibody against
the Gas1 protein, kindly provided by Randy Schekman (University of
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membrane proteins. Human P-gp and yeast Gas1 protein were
detected simultaneously on the same blot using infrared-labeled
secondary antibodies visualized at two different ﬂuorescence chan-
nels, 700 and 800 nm. The blot was developed and quantiﬁed by
Odyssey Infrared Imaging System (LI-COR Biosciences, http://www.
licor.com) following the manufacturer’s protocol.
Construction of GFP-fused P-gp variant strains. A codon-opti-
mized GFP gene for yeast, yEGFP1 [42], was ampliﬁed by PCR with
oligonucleotide primers designed to allow in-frame fusion to the 39
end of ABCB1 reference and its variants in a yeast expression vector
by recombination following transformation into yeast [43]. The
presence of yEGFP in the construct was veriﬁed by colony PCR and
DNA sequencing.
Visualization of P-gp-GFP fusion proteins. For ﬂuorescence
microscopy, cells were grown in synthetic medium without trypto-
phan to minimize autoﬂuorescence. Imaging was done at room
temperature using an Olympus IX-71 microscope equipped
with 1003 NA1.4 objectives and Orca-II camera (http://www.
olympusamerica.com). ImageJ (http://rsb.info.nih.gov/ij) was used for
manipulation of images.
Statistical analysis. The probability of a statistically signiﬁcant
difference between the mean values of two datasets was determined
by one-way ANOVA with Dunnett’s post-test using GraphPad Prism
version 4.03 for Windows, GraphPad Software (http://www.graphpad.
com).
Supporting Information
Figure S1. Schematic Secondary Structure of P-Gp and Its Coding
Variants
The variants were from the dataset of the Pharmacogenetics of
Membrane Transporters study [20]. Nonsynonymous SNPs are shown
in red and synonymous SNPs are in green. The SNPs prioritized and
analyzed in this study are shaded.
Found at doi:10.1371/journal.pgen.0030039.sg001 (46 KB PPT).
Table S1. Yeast Strains and Plasmids Used in This Study
Found at doi:10.1371/journal.pgen.0030039.st001 (39 KB DOC).
Table S2. Alignment and Frequency of ABCB1 Haplotypes Containing
Nonsynonymous Variants
Found at doi:10.1371/journal.pgen.0030039.st002 (92 KB DOC).
Table S3. Survival of Yeast Expressing the P-Gp Variants on a High
Concentration of Daunorubicin and Doxorubicin
Found at doi:10.1371/journal.pgen.0030039.st003 (38 KB DOC).
Table S4. The EC50 or EC30 Values of the P-Gp Variants for Four
Drug Substrates
Found at doi:10.1371/journal.pgen.0030039.st004 (50 KB DOC).
Table S5. Oligonucleotides Used in Site-Directed Mutagenesis
Found at doi:10.1371/journal.pgen.0030039.st005 (30 KB DOC).
Accession Numbers
The Entrez (http://www.ncbi.nlm.nih.gov/Entrez) accession numbers
for the genes described in this paper are 5243 for human ABCB1,
1576 for human CYP3A4, 854324 for yeast PDR5, 851574 for yeast
SNQ2, 853198 for yeast YOR1, 853671 for yeast STE6, and 855355 for
yeast GAS1.
The RefSeq (http://www.ncbi.nlm.nih.gov/entrez/query.
fcgi?db=OMIM) accession number for human ABCB1 cDNA carried
in plasmid pJR2702 is M14758.1.
The Online Mendelian Inheritance in Man (http://www.ncbi.nlm.
nih.gov/entrez/query.fcgi?db=OMIN) accession numbers are 168600
for Parkinson’s disease, 266600 for inﬂammatory bowel disease, and
144700 for renal epithelial tumors.
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